Drug intelligence / Profile preview

Olanzapine, Risperidone, and Sulpiride Combination

Development stage
Unknown
Lead developer
Eli Lilly
Modality
Small Molecules
Administration
Oral, Intramuscular
01

Overview

This is a combination of three antipsychotic medications, each with different receptor binding profiles. Olanzapine is an atypical antipsychotic with stronger affinity for serotonin 5-HT2 receptors than dopamine D2 receptors[1][4]. Risperidone is another atypical antipsychotic that works by balancing dopamine and serotonin levels in the brain[10]. Sulpiride is a selective D2 antagonist that can enhance D2 blockade when combined with other antipsychotics[1][4].\n\nThe rationale behind combining these medications is to leverage their different receptor affinities to potentially enhance clinical efficacy in treatment-resistant schizophrenia[1][2]. While the search results don't specifically discuss the triple combination of all three drugs together, they do provide information about various dual combinations of these and similar antipsychotics.\n\nThe search results indicate that combinations of atypical antipsychotics are generally well-tolerated and may be effective for managing treatment-refractory schizophrenia[2]. Specific combinations mentioned include:\n\n- Olanzapine + sulpiride: A preliminary study showed noteworthy and rapid clinical improvement in six patients with chronic schizophrenia, supported by decreased scores on the Positive and Negative Syndrome Scale and Brief Psychiatric Rating Scale, with no bothersome side effects reported[1][4].\n\n- Clozapine + sulpiride: A Cochrane review found this combination more effective than clozapine alone, though more data was needed for firm conclusions[9].\n\n- Clozapine + risperidone: Studies showed mixed results, with one double-blind RCT showing significantly superior improvement of positive, negative, and total psychopathology, while another RCT revealed significantly inferior improvement of positive symptoms compared to placebo[9].

02

Targets

DRD3 (Dopamine receptor D3)HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on Olanzapine, Risperidone, and Sulpiride Combination.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Olanzapine, Risperidone, and Sulpiride Combination.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call